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Simple Summary: Inflammatory biomarkers have a strong prognostic value in surgically treated
patients with hepatocellular carcinoma (HCC), but the underlying pathogenic mechanism has not
been completely clarified. Conversely, nutritional biomarkers predict the outcomes after hepatic
resection for HCC but not after liver transplantation (LT). Indeed, the impact of LT on the recipient’s
nutritional status is heterogeneous, while the data on the patient’s outcome after LT in terms of
inflammatory status are limited. Therefore, to address these unsolved questions, we conducted a
retrospective analysis on 324 HCC patients treated with LT, exploring the postoperative trend up to
1 year post-LT and the prognostic value of the Platelet-to-Lymphocyte Ratio (PLR), Neutrophil-to-
Lymphocyte Ratio (NLR), Controlling Nutritional Status (CONUT), Prognostic Nutritional Index
(PNI). It was found that at 1 year post-LT, the nutritional status of liver-transplanted HCC patients
significantly improved while their inflammatory state tended to persist. Consequently, post-LT PLR
and NLR maintained a prognostic value for LT outcome while post-LT CONUT and PNI acquired it.
Abstract: Preoperative inflammatory biomarkers such as the Platelet-to-Lymphocyte Ratio (PLR)
and the Neutrophil-to-Lymphocyte Ratio (NLR) strongly predict the outcome in surgically treated
patients with hepatocellular carcinoma (HCC), while nutritional biomarkers such as the Controlling
Nutritional Status (CONUT) and the Prognostic Nutritional Index (PNI) show an analogue prognostic
value in hepatic resection (HR) but not in liver transplant (LT) cases. Data on the impact of LT on
the inflammatory and nutritional/metabolic function are heterogeneous. Therefore, we investigated
the post-LT trend of these biomarkers up to postoperative month (POM) 12 in 324 HCC patients
treated with LT. Inflammatory biomarkers peaked in the early post-LT period but at POM 3 leveled
off at values similar (NLR) or higher (PLR) than pre-LT ones. CONUT and PNI worsened in the
early post-LT period, but at POM 3 they stabilized at significantly better values than pre-LT. In
LT recipients with an overall survival >1 year and no evidence of early HCC recurrence, 1 year
post-LT NLR and PNI independently predicted patient overall survival, while 1 year post-LT PLR
independently predicted late tumor recurrence. In conclusion, at 1 year post-LT, the nutritional status
of liver-transplanted HCC patients significantly improved while their inflammatory state tended to
persist. Consequently, post-LT PLR and NLR maintained a prognostic value for LT outcome while
post-LT CONUT and PNI acquired it.
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1. Introduction
Laboratory-derived clinical biomarkers have been recently shown to provide objective,
measurable and synthetic information on the clinical status of the patient [1,2]. Moreover,
they seem to have a prognostic value for some patient outcomes [1–6]. In patients with
hepatocellular carcinoma (HCC) treated with hepatic resection (HR) or liver transplantation
(LT), the Neutrophil-to-Lymphocyte Ratio (NLR) and the Platelet-to-Lymphocyte Ratio
(PLR) have been validated as markers of systemic inflammation and immune dysfunction,
and when tested preoperatively, they have been shown to predict the risk of early death or
tumor recurrence [2–8]. On the other hand, the Controlling Nutritional Status (CONUT)
score and the Prognostic Nutritional Index (PNI), that are validated nutritional biomarkers,
have shown an analogue prognostic value in HR cases but not in the LT setting [9–12]. The
underlying pathogenic mechanism associated with such diversity is currently not known,
as very limited data are available on the effect of LT on the immuno-inflammatory and
nutritional status of the recipient. Therefore, the present study explores the postoperative
trend and prognostic value of PLR, NLR, CONUT, and PNI, aiming at (i) providing
new insights on the impact of LT on the recipient’s inflammatory and nutritional status,
(ii) trying to explain the diversified prognostic value of inflammatory and nutritional
biomarkers as preoperative variables, and (iii) testing whether these biomarkers can be
used also as postoperative surveillance parameters.
2. Materials and Methods
This is a retrospective study on a multicenter cohort of 324 HCC patients treated
with LT at the Liver-Kidney Transplant Unit—Udine University Hospital (n = 126), and
at the HPB Surgery and Transplantation Unit—United Hospitals of Ancona (n = 198),
between January 2006 and December 2018. Demographic and clinical data of recipients
and intraoperative and postoperative outcomes were reviewed from the local electronic
database. The pre-transplant assessment was previously described in [10]. CONUT score
was calculated as previously described [10], while PNI was calculated according the
following formula [10 * serum albumin (g/dL) + 0.005 * Total lymphocyte (cells/mm2)]
(PNI). CONUT score, Model for end-stage liver disease (MELD) score, PNI, PLR, and NLR,
were calculated on laboratory test data on admission before LT. As postoperative variables,
PLR, NLR, CONUT, and PNI were calculated at postoperative day (POD) 1, 3, 5, and 7,
and at postoperative month (POM) 3, 6, and 12. Standard post-transplant management
for clinical surveillance over postoperative complications as well as immunosuppressant
regimens and post-discharge patient follow-up protocols were previously described in [10].
Categorical variables were expressed by frequencies and percentage, while continuous
variables were expressed by mean ± standard deviation (SD) or median (interquartile range
(IQR)), as appropriate. General Linear Model for measured repeats was used to compare
post-LT values of PLR, NLR, PNI, and CONUT at determined time points, with their
respective pre-LT values, after the assumptions had been verified. Bonferroni’s correction
for multiple comparisons was applied. Overall survival (OS) was defined as the time
(months) from liver transplantation to either death or last observation and was described
according to the Kaplan–Meier approach. Univariate Cox regression was used to estimate
prognostic value of pre-LT and post-LT biomarkers for OS, after the assumption of the
proportional hazard was verified. The proportional hazard assumption was tested using
the Schoenfeld residual test. Death was considered as a competing risk event because
death for causes unrelated to HCC precludes the occurrence of HCC recurrence. The
cumulative incidence method was used to estimate HCC recurrence accounting for the
presence of competing risks. Based on the method of Fine and Gray, univariate competing-
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risk regression was used to explore whether pre- and post-LT biomarkers were associated
with HCC recurrence. The competing-risk regression model is based on the hazard of the
subdistribution and provides a simple relationship between covariates and cumulative
incidence. In case of HCC recurrence within 1 year post-LT (early recurrence), later
biomarker data after recurrence were excluded from the analysis.
To test the surveillance value as prognostic factor of 1-year post-LT inflammatory and
nutritional biomarkers, a sub-group analysis was performed in patients with an OS > 1
year and no evidence of early HCC recurrence (n = 266). A univariate and stepwise
multivariate Cox regression was used for OS analysis, while a univariate and stepwise
multivariate competing-risk regression was used for HCC recurrence analysis. The risk of
multicollinearity was evaluated by means of the variance inflation factor. Variables of p
less than 0.10 during univariate analysis were included in multivariable analysis.
Univariate linear regression model was used to explore the potential determinants
of prognostically significant biomarkers among HCC features, MELD score, and Child–
Pugh classification.
The analyses were performed using Stata/SE 15.1 (Stata Corp LP, United States). The
present study was approved by the local Institutional Review Board.
3. Results
The demographic and clinical data on recipients, HCC histopathology characteristics,
surgical details, and donor and graft characteristics are summarized in Table 1. The median
age at transplantation was 58 years (52–62) with a median MELD score of 12 (9–16) and
median BMI of 25.3 (23.2–28.1). At pathologic examination of the explanted liver, the
median number of HCC lesions was 2 (1–3) with bilobar distribution in 25.3% of cases
and a median maximum diameter of 2.3 (1.5–3) cm. The median follow-up time was
50.2 months (21.9–91.4).
Table 1. Demographic and clinical data on recipients, graft characteristics, and surgical details.
Gender (M:F) 291:33
Age (years) 58 (52–62)
BMI 25.3 (23.2–28.1)
Pre-LT diabetes (%) 54 (16.9%)
HIV positivity (%) 29 (9.0%)
HCV positivity (%) 180 (55.6%)
HBV positivity (%) 70 (21.6%)
Alcohol abuse (%) 96 (29.6%)
MELD score 12 (9–16)
Child–Pugh score (%)
- A 139 (42.9%)
- B 122 (37.6%)
- C 62 (19.5%)
Pre-LT PLR 74.2 (50.3–108.5)
1 year post-LT PLR 118.2 (79.1–161.5)
Pre-LT NLR 2.9 (1.9–4.8)
1 year post-LT NLR 2.4 (1.7–3.7)
Pre-LT PNI 38.6 (34.5–44.1)
1 year post-LT PNI 45.6 (41.9–49.5)
Pre-LT CONUT 5 (3–7)
1 year post-LT CONUT 2 (1–3)
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Table 1. Cont.
Pre-LT AFP, (ng/L) 9.8 (4.6–40.2)
Donor age (years) 61.4 (50.1–72.9)
Donor BMI 25.8 (23.7–27.8)
Total ischemia time (min) 470 (401–550)
Packed blood cells transfusion, (UI) 3 (0–7)
Frozen fresh plasma transfusion, (mL) 1000 (0–2000)
Tumor number 2 (1–3)
Tumor max diameter (cm) 2.3 (1.5–3)
Bilobar tumor distribution (%) 82 (25.3%)
Edmonson–Steiner grading (%)
- Complete necrosis 12 (3.7%)
- G1 54 (16.6%)
- G2 172 (53.1%)
- G3 80 (24.7%)
- G4 6 (1.9%)
Microvascular invasion (%) 50 (15.4%)
AFP: Alpha-Fetoprotein, BMI: body mass index, CONUT: controlling nutritional status, HBV: hepatitis B virus,
HCV: hepatitis C virus, HIV: human immunodeficiency virus, HCC: hepatocellular carcinoma, LT: liver trans-
plantation, MELD: Model for end-stage liver disease, NLR: Neutrophil-to-Lymphocyte Ratio, PLR: Platelet-to-
Lymphocyte Ratio, PNI: Prognostic Nutritional Index.
3.1. Post-Transplant Trend of Inflammatory and Nutritional Biomarkers
The preoperative values of PLR, NLR, PNI, and CONUT were 74.2 (50.3–108.5),
2.9 (1.9–4.8), 38.6 (34.5–44.1), and 5 (3–7), respectively. The postoperative trend of these
scores is shown in Figure 1. Compared to preoperative values, the nutritional biomarkers
showed a significant worsening in the early post-LT period (Figure 1, decrease of PNI and
increase of CONUT), followed by a significant improvement at POM 3 which tended to
stabilize thereafter for CONUT while further significantly improving for PNI. At 1-year
post-LT, the median value of PNI and CONUT were 45.8 (41.9–49.5) and 2 (1–4). Both
PLR and NLR peaked on POD 1 and subsequently decreased, still maintaining values
significantly higher than pre-LT ones. At POM 3, both inflammatory biomarkers leveled
off at values that were similar to pre-LT for NLR (1-year post-LT value 2.4 [1.7–3.7], p 0.328)
but significantly higher for PLR (118.2 [79.1–161.5], p < 0.001).
3.2. Overall Survival
The overall patient survival at 1, 3, and 5 years was 85.6%, 76.1%, and 70.1%, respec-
tively. In univariate analysis (Table 2), Pre-LT PLR, pre-LT NLR, but not pre-LT PNI nor
pre-LT CONUT were confirmed as significant prognostic factors, as previously reported [10].
Moreover, analyzing the inflammatory and nutritional biomarkers as postoperative values,
NLR and PLR maintained a stable significant prognostic value from POD 3 and POD 7,
respectively, while PNI and CONUT acquired a stable prognostic value since POD 7.
3.3. HCC Recurrence
The cumulative incidence of HCC recurrence at 1, 3, and 5 years was 4.4%, 12.2%,
15.8%, respectively. In univariate analysis (Table 2), pre-LT PLR, pre-LT NLR, as well as post-
LT PLR since POM 6, NLR since POM 3, and PNI at POM 12, predicted tumor recurrence.
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Table 2. Univariate analysis of prognostic value for mortality and tumor recurrence of inflammatory
and nutritional biomarkers, pre- and post-LT, in the whole study population (n = 324).
Mortality HCC Recurrence




pre-LT 1.004 1.002–1.006 <0.001 1.005 1.002–1.007 0.001
POD 1 1.001 0.999–1.002 0.399 1.001 0.999–1.003 0.196
POD 3 1.001 0.998–1.003 0.354 1.001 0.998–1.004 0.384
POD 5 1.001 0.998–1.004 0.295 0.999 0.996–1.003 0.982
POD 7 1.003 1.001–1.005 0.012 0.999 0.996–1.002 0.769
POM 3 1.003 1.001–1.005 0.003 1.001 0.998–1.003 0.333
POM 6 1.005 1.004–1.008 <0.001 1.003 1.001–1.006 0.018
1 year post-LT 1.005 1.003–1.007 <0.001 1.003 1.001–1.006 0.010
NLR
pre-LT 1.058 1.030–1.087 <0.001 1.041 1.003–1.081 0.036
POD 1 1.007 0.998–1.016 0.116 1.001 0.988–1.013 0.886
POD 3 1.013 1.001–1.025 0.032 0.989 0.964–1.016 0.456
POD 5 1.029 1.013–1.044 <0.001 0.977 0.944–1.011 0.187
POD 7 1.054 1.039–1.069 <0.001 0.953 0.913–1.001 0.126
POM 3 1.005 1.001–1.011 0.024 1.008 1.002–1.016 0.017
POM 6 1.210 1.158–1.266 <0.001 1.071 1.013–1.133 0.016
1 year post-LT 1.058 1.030–1.087 <0.001 1.157 1.007–1.331 0.040
PNI
pre-LT 0.988 0.962–1.014 0.382 1.018 0.982–1.057 0.315
POD 1 0.952 0.915–1.000 0.145 1.029 0.975–1.086 0.288
POD 3 0.984 0.942–1.027 0.473 0.999 0.943–1.058 0.977
POD 5 0.980 0.941–1.020 0.326 1.006 0.944–1.072 0.840
POD 7 0.956 0.916–0.998 0.044 1.009 0.948–1.073 0.776
POM 3 0.943 0.911–0.976 0.001 1.005 0.954–1.059 0.834
POM 6 0.911 0.874–0.949 <0.001 1.008 0.963–1.054 0.722
1 year post-LT 0.862 0.818–0.908 <0.001 0.911 0.844–0.984 0.019
CONUT
pre-LT 0.956 0.876–1.044 0.326 0.936 0.837–1.047 0.251
POD 1 1.071 0.944–1.216 0.282 0.850 0.719–1.005 0.158
POD 3 1.003 0.910–1.106 0.944 0.970 0.850–1.108 0.662
POD 5 1.006 0.902–1.122 0.904 1.001 0.833–1.204 0.987
POD 7 1.158 1.017–1.319 0.026 0.959 0.812–1.133 0.628
POM 3 1.211 1.075–1.365 0.002 1.002 0.832–1.207 0.980
POM 6 1.335 1.195–1.493 <0.001 0.951 0.797–1.135 0.582
1 year post-LT 1.304 1.099–1.546 0.002 1.107 0.812–1.508 0.518
CONUT: controlling nutritional status, HR: hazard ratio, LT: liver transplantation, NLR: Neutrophil-to-
Lymphocyte Ratio, PLR: Platelet-to-Lymphocyte Ratio, PNI: Prognostic Nutritional Index, POD: postoperative
day, POM: postoperative month, SHR: subdistribution hazard ratio, bold numbers mark statistical significance.
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3.4. Late (>1 Year Post-LT) Outcomes
We further investigated the potential predictive factors for OS and HCC recurrence in
patients with an OS > 1 year and no evidence of early HCC recurrence (n = 266).
In univariate analysis, 1-year post-LT PLR, NLR, PNI, and CONUT as well as units of
packed blood cells transfused at LT, ml of frozen fresh plasma transfused at LT and HCC
recurrence were significantly associated with OS (Table 3). In multivariate analysis, HCC
recurrence, 1 year post-LT NLR and 1 year post-LT PNI maintained statistical significance
(units of packed blood cells transfused and ml of frozen fresh plasma showed collinearity,
therefore only units of packed blood cells transfused was considered in the multivariate
model) (Figure 2).
Table 3. Univariate and multivariate Cox analysis of prognostic factors for OS, in subgroup analysis of patients with overall
survival (OS) > 1 year and no early HCC recurrence (n = 266).
Univariate Analysis Multivariate Analysis
Factors HR 95% Conf.Interval p-Val HR 95% Conf. Interval p-Val
Sex
- male 1
- female 0.850 0.340–2.123 0.728
Age 1.016 0.981–1.052 0.367
Pre-LT BMI 0.955 0.885–1.031 0.244
Pre-transplant diabetes 0.870 0.395–1.917 0.730
HIV positivity 1.115 0.481–2.590 0.798
HCV positivity 0.892 0.548–1.451 0.646
HBV positivity 0.870 0.4945–1.533 0.631
Alcohol abuse 1.523 0.915–2.533 0.105
MELD score 0.971 0.926–1.018 0.236
Child–Pugh score 0.839 0.585–1.205 0.343
Donor age 1.003 0.988–1.018 0.654
Donor BMI 0.987 0.925–1.054 0.706
Total ischemia time 1.001 0.999–1.003 0.303
Packed blood cells
transfusion 1.044 1.004–1.085 0.029 1.058 1.004–1.117 0.040
Frozen fresh plasma
transfusion 1.001 1.000–1.002 0.046
Pre-LT AFP 1.000 0.999–1.000 0.277
HCC recurrence 3.916 2.339–6.556 <0.001 5.428 2.859–10.307 <0.001
1 year post-LT PLR 1.005 1.002–1.007 <0.001
1 year post-LT NLR 1.332 1.194–1.486 <0.001 1.218 1.053–1.408 0.008
1 year post-LT PNI 0.863 0.814–0.915 <0.001 0.913 0.851–0.978 0.011
1 year post-LT CONUT 1.286 1.067–1.550 0.008
AFP: Alpha-Fetoprotein, BMI: body mass index, CONUT: controlling nutritional status, HBV: hepatitis B virus, HCC: hepatocellular
carcinoma, HCV: hepatitis C virus, HIV: human immunodeficiency virus, HR: hazard ratio, LT: liver transplantation, MELD: Model for
end-stage liver disease, NLR: Neutrophil-to-Lymphocyte Ratio, PLR: Platelet-to-Lymphocyte Ratio, PNI: Prognostic Nutritional Index, bold
numbers mark statistical significance.
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Figure 2. Predictive value of NLR, PNI, and PLR for long-term outcomes, using conventional
clinically-oriented cutoffs [2,3,5–8,11,12].
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The univariate competing-risk regression analysis showed that 1 year post-LT PLR,
NLR and PNI as well as tumor number, tumor maximum diameter, grading, and mi-
crovascular invasion were significant risk factors for late tumor recurrence. In multivariate
analysis, 1-year post-LT PLR, tumor number, tumor maximum diameter, grading, and
microvascular invasion were identified as independent predictors of late HCC recurrence
(Table 4) (Figure 2).
Table 4. Univariate and multivariate analysis of prognostic factors for HCC recurrence, in subgroup analysis of patients
with OS > 1 year and no early HCC recurrence (n = 266).
Univariate Analysis Multivariate Analysis
Factors SHR 95% Conf.Interval p-Val SHR 95% Conf. Interval p-Val
Sex
- male 1
- female 2.093 0.844–5.190 0.211
Age 1.009 0.969–1.059 0.702
Pre-LT BMI 0.952 0.864–1.051 0.334
Pre-transplant diabetes 0.336 0.081–1.403 0.135
HIV positivity 1.042 0.327–3.316 0.944
HCV positivity 0.565 0.286–1.119 0.202
HBV positivity 1.917 0.959–3.830 0.165
Alcohol abuse 1.042 0.502–2.163 0.911
MELD score 0.939 0.857–1.028 0.177
Child–Pugh score 0.587 0.346–1.995 0.148
Donor age 0.994 0.974–1.015 0.622
Donor BMI 0.931 0.847–1.024 0.143
Total ischemia time 1.001 0.998–1.003 0.530
Packed blood cells
transfusion 0.994 0.925–1.070 0.891
Frozen fresh plasma
transfusion 0.999 0.999–1.000 0.363
Pre-LT AFP 1.000 0.999–1.001 0.341
1 year post-LT PLR 1.004 1.001–1.006 0.009 1.005 1.001–1.006 0.008
1 year post-LT NLR 1.166 1.009–1.349 0.038
1 year post-LT PNI 0.900 0.830–0.975 0.011
1 year post-LT CONUT 1.165 0.838–1.619 0.364
Tumor number 1.407 1.203–1.646 <0.001 1.504 1.26–1.795 <0.001
Tumor max diameter 1.284 1.116–1.478 0.001 1.344 1.145–1.578 <0.001
Edmonson–Steiner
grading 2.250 1.372–3.687 0.001 2.030 1.045–3.945 0.037
Microvascular invasion 4.859 2.338–10.100 <0.001 3.511 1.605–7.681 0.032
AFP: Alpha-Fetoprotein, BMI: body mass index, CONUT: controlling nutritional status, HBV: hepatitis B virus, HCC: hepatocellular
carcinoma, HCV: hepatitis C virus, HIV: human immunodeficiency virus, LT: liver transplantation, MELD: Model for end-stage liver disease,
NLR: Neutrophil-to-Lymphocyte Ratio, PLR: Platelet-to-Lymphocyte Ratio, PNI: Prognostic Nutritional Index, SHR: subdistribution hazard
ratio, bold numbers mark statistical significance.
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3.5. Predictive Factors of Pre-LT and 1 Year Post-LT Inflammatory and Nutritional Biomarkers
HCC features (number, max diameter, grading, microvascular invasion) and pre-LT
liver disease severity (MELD score, Child–Pugh class) were tested as potential determinants
of pre-LT PLR, pre-LT NLR, as well as PLR, NLR, and PNI at 1 year post-LT (Table 5). In the
linear regression model, it was found that pre-LT PLR was significantly predicted by tumor
grading and tumor number, while pre-LT NLR was predicted by MELD score, Child–Pugh
score and tumor grading; both 1-year post-LT PLR and post-LT NLR were significantly
predicted by microvascular invasion and pre-LT AFP serum levels. Additionally, 1-year
post-LT NLR was also predicted by tumor max diameter. Microvascular invasion and
grading were also identified as significant determinants of 1-year post-LT PNI. Pre-LT PNI
was not predicted by HCC features but only by pre-LT liver disease severity severity (data
not shown).
Table 5. Linear regression analysis of predictors of PLR, NLR, and PNI.
Factors RegressionCoefficient 95% Conf. Interval p-Val
Regression
Coefficient 95% Conf. Interval p-Val
PLR
pre-LT 1 year post-LT
MELD score 0.255 −0.959 to 1.471 0.679 0.656 −1.144 to 2.457 0.473
Child–Pugh score 7.635 −3.347 to 18.619 0.172 −4.916 −20.333 to 10.501 0.530
Pre-LT AFP 0.001 −0.0136 to 0.016 0.845 0.032 0.013–0.050 0.001
Tumor number 5.408 0.018 to 10.797 0.049 0.256 −7.296 to 7.810 0.947
Tumor max diameter 0.645 −5.470 to 6.760 0.836 1.799 −5.061 to 8.660 0.606
Edmonson–Steiner
grading 10.108 1.162 to 21.378 0.050 9.166 −6.697 to 25.031 0.256
Microvascular invasion 13.810 −9.167 to 36.789 0.238 36.989 3.763 to 70.215 0.029
NLR
pre-LT 1 year post-LT
MELD score 0.196 0.115 to 0.277 <0.001 −0.005 −0.053 to 0.041 0.816
Child–Pugh score 2.095 1.368 to 2.822 <0.001 0.071 −0.344 to 0.486 0.736
Pre-LT AFP −0.000 −0.000 to.008 0.928 0.081 0.035 to 0.132 0.002
Tumor number 0.172 −0.205 to 0.549 0.370 0.054 −0.146 to 0.255 0.595
Tumor max diameter −0.367 −0.790 to 0.055 0.089 0.185 0.007 to 0.364 0.042
Edmonson–Steiner
grading 0.836 0.051 to 1.621 0.037 0.286 −0.128 to 0.701 0.175
Microvascular invasion 0.887 −0.728 to 2.503 0.281 1.125 0.252 to 1.999 0.012
PNI
1 year post-LT
MELD score −0.022 −0.153 to 0.107 0.729
Child–Pugh score −0.405 −1.539 to 0.729 0.482
Pre-LT AFP −0.000 −0.002 to 0.000 0.226
Tumor number −0.218 −0.763 to 0.326 0.431
Tumor max diameter −0.022 −0.519 to 0.473 0.927
Edmonson–Steiner
grading −1.345 −2.463 to −0.228 0.019
Microvascular invasion −3.785 −6.142 to −1.427 0.002
AFP: Alpha-Fetoprotein, CONUT: controlling nutritional status, LT: liver transplantation, MELD: Model for end-stage liver disease,
NLR: Neutrophil-to-Lymphocyte Ratio, PLR: Platelet-to-Lymphocyte Ratio, PNI: Prognostic Nutritional Index, bold numbers mark
statistical significance.
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4. Discussion
LT has a radical impact on the immune–inflammatory and metabolic–nutritional
status of the recipient. The removal of the chronically inflamed cirrhotic liver and the
regaining of normal liver function, with recovery from the complications of liver failure and
portal hypertension, contrast with a high surgical invasiveness, potentially severe surgical
complications, and immunosuppressant toxicity [13,14]. However, the data assessing the
post-transplant outcome in terms of inflammatory state are very limited [1,15], while data
on the post-transplant metabolic recovery are extremely heterogeneous, variably reporting
a significant increase in the prevalence of metabolic syndrome and an incomplete recovery
from pre-LT sarcopenia [16–18].
In the present investigation, the early postoperative period was characterized by a
significant worsening of the nutritional status of recipients, probably due to the catabolic
state induced by surgical stress and inflammatory response, postoperative fasting, and
surgical complications. This result was in line with previous studies investigating other
malnutrition features, such as sarcopenia [16]. However, in mid/long-term follow-up,
CONUT and PNI tended to significantly improve, thus supporting the beneficial effect
of LT on nutrition [19]. Moreover, it was shown that nutritional biomarkers did not
have any prognostic value as preoperative variables, but actually acquired it as post-
transplant ones. It may be speculated that recipients regained a nutritional profile similar
to the general population after LT, and those who became malnourished or failed to
recover from pre-LT malnutrition despite LT, had an increased risk of early death or tumor
recurrence. Of course, obesity, diabetes, and dyslipidemia, rather than undernutrition,
currently represent the most frequent and impactful long-term complications after LT, due
to the inherent risk of cardiovascular disease and death [18,19]. However the evidence that
1-year post-LT PNI was predicted by HCC features on explanted livers further highlights
the pathogenic association between malnutrition, aggressive tumor biology, and risk of
tumor recurrence [11,12]. Unfortunately, no other studies in LT recipients are available
for comparison with our results. However, the prognostic value of postoperative PNI has
been previously explored in an HR setting. In patients with HCC within Milan criteria
and hypersplenism, 1-month post-HR PNI was identified as a significant predictive factor
for survival and tumor recurrence [20]. Furthermore, a decrease of PNI value at 1 year
post-HR, compared to preoperative values, was found as a negative prognostic factor in
HBV-positive patients with HCC within Milan criteria [21]. Therefore, in long-term follow
up, PNI may be effectively used in clinical practice as a reliable prognostic biomarker. The
early identification of those patients who did not benefit from the metabolic curative effect
of LT may not only prompt a therapeutic intervention but also warn of an increased risk of
HCC recurrence.
On the contrary, the analysis of the postoperative trend of inflammatory biomarkers
showed that LT may not sustain a significant improvement of the recipients’ inflammatory
status. As a matter of fact, in the present study it was shown that since POM 3, both
PLR and NLR leveled off at values that were similar to pre-LT for NLR, and significantly
higher for PLR. Parisi et al. [22] measured these inflammatory biomarkers at pre-LT, 1
month and 6 months post-LT in 150 HCC patients within Milan criteria, and found the
same postoperative trend with similar median values: PLR, pre-LT 68 (present study 74.1),
6 months post-LT 135 (124.4); NLR, pre-LT 2.2 (2.9), 6 months post-LT 2.5 (2.6). The available
data on normal values of PLR and NLR in healthy individuals are quite heterogeneous,
probably due to the presence of demographic differences among the study populations.
As a matter of fact, race, gender, age, BMI, and smoking have been variably identified as
significant determinants of inflammatory biomarkers [23,24]. In a European study [25]
on active adults in good health, the mean NLR value was 1.65, while in two Chinese
studies [24,26] on healthy adult/old subjects the median NLR value was 1.77 and 1.72,
respectively, and the median PLR value was 99 and 108, respectively. In the present study,
the median NLR and PLR values at 1 year post-LT were 2.4 and 118.2, respectively, which
are indeed higher than the aforementioned reference values. An American study [23]
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actually reported a mean NLR value of 2.15, but the study population also comprised
subjects with comorbidities, such as diabetes, cardiovascular disease, or obesity, which are
all associated with chronic pro-inflammatory states [23,27].
In contrast with our results as well as with several previous meta-analyses [1–8], none
of the inflammatory biomarkers, either as pre-LT or post-LT variables, were identified as
significant predictors of HCC recurrence in the study of Parisi et al. [22]. To be noticed, a
competing-risk regression model was not used in such analysis and the potential predictors
of OS were not investigated. As already underlined by the Authors, the study population
was characterized by relatively favorable HCC features which may have influenced the
results. On the contrary, in the present investigation, PLR and NLR not only predicted
OS and HCC recurrence as pre-LT variables, but also maintained their prognostic value
in the mid/long-term after LT. Similarly, in an HR setting, a significant increase of PLR at
1 month post-HR (compared to preoperative values) was found as an independent risk
factor for early death and tumor recurrence in HBV-positive patients with early HCC [28].
Previous studies have already reported a significant correlation between pre-LT inflam-
matory biomarkers and biological tumor behavior, such as grading and microvascular
invasion [1,29]. However our investigation demonstrated that such pathogenic association
was maintained even at 1 year post-LT. Such results may enforce the hypothesis that a
significant pro-inflammatory state may be actually reactive to a tumor that has already
reached the stage of microscopic systemic disease, for whom LT cannot be curative [1,29].
Of course, other determinants of recipients’ post-LT inflammatory status may be implicated,
such as graft rejection, immunosuppressant therapies, liver disease recurrence, infections,
or metabolic complications [22]. However, it has been extensively demonstrated that
chronic inflammation may not only impair an effective immunosurveillance but also act as
a primary trigger of tumor progression and metastasis [1,22]. In particular, neutrophil and
platelets could promote metastatic dissemination via increased levels of the cytokine vas-
cular endothelial growth factor, angiogenesis-regulating chemokines, and proteases [1,29].
It was interesting to notice that the same independent and specific prognostic value of
NLR (OS) and PLR (HCC recurrence) was concordantly identified at 1 year post-LT, in the
present study, as well as at pre-LT, in our previous investigation [10]. Such results further
enforce the potential role of PLR and NLR in the pre-LT selection of HCC patients.
The precision medicine model, which integrates clinical, molecular, and genetic data to
achieve a clinical management that is tailored to the specific characteristics and risks of each
patient, is emerging as the most effective health care strategy [30,31]. This is particularly
evident in LT candidates with HCC, where the pathogenic interaction among tumor cells,
the patient’s immune system and metabolic function, surgical invasiveness, and post-LT
immunosuppressant therapies is very tight and has significant implications for long-term
outcomes. Biomarkers are the cornerstone of precision medicine, but their identification as
well as their real clinical effectiveness depend on the exact understanding of the disease
pathogenesis [30,31]. Therefore, further studies will be surely warranted to explore in
particular the potential association between inflammatory biomarkers and circulating
tumor cells or distant micrometastasis, as well as to identify those post-LT clinical factors
which significantly sustain a persistent pro-inflammatory state in LT recipients.
This study presents several limitations: it used a retrospective approach for the data
analysis; the immune–inflammatory and metabolic–nutritional status of the patients was
investigated only by laboratory biomarkers; the prevalence of metabolic syndrome or
pathologic body mass composition features (visceral obesity, sarcopenia), immunosup-
pressant dosages, post-LT changes of spleen size, and post-LT complications were not
specifically investigated.
5. Conclusions
LT seems to promote an efficacious recovery and normalization of the nutritional
status of recipients, but those who do not benefit from this effect at long-term follow-
up are at increased risk of poor survival and HCC recurrence. With this perspective, a
Cancers 2021, 13, 513 13 of 14
routine monitoring of PNI may represent a cost-effective, easy, and prognostically impactful
strategy. On the other hand, the effect of LT on the recipient inflammatory status seems
limited as in long-term follow-up post-LT PLR and NLR tend to level off at values similar
to pre-LT, and maintain the same prognostic value. HCC in LT candidates with high PLR
and/or NLR may have a more aggressive biology, requiring these patients to be thoroughly
and more carefully assessed in the pre-LT workup. Moreover, NLR and PLR may be also
used as reliable prognostic parameters for long-term clinical surveillance.
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